You are here
Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol. 1996;106:462-468.
Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotypic changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001;97:3574-3580.
Borowitz MJ, Bray R, Gascoyne R, et al. U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry. 1997;30:236-244.
Braylan RC, Atwater SK, Diamond L, et al. U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data reporting. Cytometry. 1997;30:245-248.
Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003;121:823-838.
Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol. 2003;123:243-252.
Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691-2696.
DiGiuseppe JA, Borowitz MJ. Clinical applications of flow cytometric immunophenotyping in acute lymphoblastic leukemia. In: Stewart CC, Nicholson JKA, eds. Immunophenotyping. New York: Wiley-Liss; 2000:161-180.
Faber J, Kantarjian H, Roberts MW, et al. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med. 2000;124;92-97.
Jennings CD, Foon KA. Recent advances in flow cytometry: applications to the diagnosis of hematologic malignancy. Blood.1997;90:2863-2892.
Jiann-Shiuh C, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115-2120.
Kansal R, Deeb G, Barcos M, et al. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction. A report of 15 patients. Am J Clin Pathol. 2004;121:512-525.
Kappelmayer J, Gratama JW, Karaszi E, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods. 2000;242:53-65.
Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol. 1999;111:467-476.
Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.Am J Clin Pathol. 1998;109:211-220.
Krasinskas AM, Wasik MA, Kamoun M, et al. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol. 1998;110:797-805.
Lai R, Juco J, Lee SF, et al. Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias. Am J Clin Pathol. 2000;113:823-830.
Orfao A, Ortuno F, de Santiago M, et al. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry. 2004;58A:62-71.
Paietta E, Goloubeva O, Neuberg D, et al. A surrogate marker profile for PML/RARa expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry. 2004;59B:1-9.
San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 2001;98:1746-1751.
San Miguel JF, Vidriales MB, Orfao A. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukemia (AML). Bailliere’s Best Practice in Clinical Hematology.2002;15:105-118.
Stelzer GT, Goodpasture L. Use of multiparametric flow cytometry and immunophenotyping for the diagnosis and classification of acute myeloid leukemia. In: Stewart CC, Nicholson JKA, eds. Immunophenotyping. New York/: Wiley-Liss; 2000:215-259.
Stewart CC, Behm FG, Carey JL, et al. U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations. Cytometry. 1997;30:231-235.
Babusikova O, Tomova A. Hairy cell leukemia: early immunophenotypical detection and quantitative analysis by flow cytometry.Neoplasma. 2003;50:350-356.
Cornfield DB, Mitchell Nelson DM, Rimsza LM, Moller-Patti D, Braylan RC. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells. Am J Hematol. 2001;67:223-226
Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol. 2004;75:107-109.
Tytherleigh L, Taparia M, Leahy MF. Detection of hairy cell leukaemia in blood and bone marrow using multidimensional flow cytometry with CD45-PECy5 and SS gating. Clin Lab Haematol. 2001;23:385-390.
Wu ML, Kwaan HC, Goolsby CL. Atypical hairy cell leukemia. Arch Pathol Lab Med. 2000;124:1710-1713.
Deneys V, Michaux L, Leveugle P, et al. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression. Leukemia. 2001;15:1458-1465.
Dong HY, Gorczyca W, Liu Z, et al. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol. 2003;119:218-230.
Gong JZ, LagooAS/place />, Peters D, Horvatinovich J, Benz P, Buckley PJ. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897.
Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol. 1996;105:451.
Liu Z, Dong HY, Gorczyca W, et al. CD5-mantle cell lymphoma. Am J Clin Pathol. 2002;118:216-224.
Molot R, Meeker T, Wittwer C, et al. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas.Blood. 1994;83:1626.
Molina TJ, Delmer A, Cymbalista F, et al. Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. Virchows Arch. 2000;437:591-598.
Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohistochemical analysis of small lymphocyticlymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998;110:582-589.
Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107:121-131.
Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Clin Lab Med. 1993;81:3382-3387.
Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658.
Lima M, Teixeira MA, Fonseca S, et al. Immunophenotypic aberrations, DNA content, and cell cycle analysis of plasma cells in patients with myeloma and monoclonal gammopathies. Blood Cells Mol Dis. 2000;26:634-645.
Nowak R, Oelschlagel U, Range U, et al. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.Bone Marrow Transplant. 1999;23:895-900.
Ocqueteau M, Orfao A, Garcia-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95:489-493.
Pope B, Brown R, Gibson J, Joshua D. The bone marrow plasma cell labeling index by flow cytometry. Cytometry. 1999;38:286-292.
Pope B, Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
Ruiz Arguelles GJ, San Miguel JF. Cell surface markers in multiple myeloma. Mayo Clin Proc. 1994;69:684.
San Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol. 1995;8:735-759.
Zandecki M, Facon T, Bernardi F, et al. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol. 1995;48:548-552.
Ahmad E, Kingma DW, Jaffe ES, et al. Flow cytometric immunophenotypic research paper profiles of mature gamma delta T cell malignancies involving peripheral blood and bone marrow. Clinical Cytometry. 2005;67B:6-12.
Al Shanqeety O, MouradWA/place />. Diagnosis of peripheral T-cell lymphoma by fine-needle aspiration biopsy: a cytomorphologic and immunophenotypic approach. Diagn Cytopathol. 2000;23:375-379.
Chan WC, Gu LB, Masih A, et al. Large granular lymphocyte proliferation with the natural killer-cell phenotype. Am J Clin Pathol. 1992;97:353-358.
Cook JR, Craig FE, Swerdlow SH. Benign CD10-positive T cells in reactive lymphoid proliferations and B-cell lymphomas. Mod Pathol. 2003;16:879-885.
Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Clin Lab Med. 1996;88:4265-4274.
Galindo LM, Garcia FU, HanauCA/place />, et al. Fine-needle aspiration biopsy in the evaluation of lymphadenopathy associated with cutaneous T cell lymphoma (Mycosis Fungoides/Sezary syndrome). Am J Clin Pathol. 2000;113:865-871.
Gorczyca W, Weisberger J, Liu Z, et al. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry.Cytometry. 2002;50:177-190.
Hastrup N, Ralfkiaer E, Pallesen G. Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol. 1989;42:398.
Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol. 2001;116:512-526.
Kuchnio M, Sausville EA, Jaffe ES, et al. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am J Clin Pathol. 1994;102:856-860.
Lima M, Almeida J, dos Anjos TM, et al. Utility of flow cytometry immunophenotyping and DNA ploidy studies for diagnosis and characterization of blood involvement in CD4+ Sezary’s syndrome. Haematologica. 2003;88:874-887.
Macon WR, Williams ME, Greer JP, et al. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Clin Lab Med. 1996;87:1474-1483.
Rakozy CK, Mohamed AN, Vo TD, et al. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse. Am J Clin Pathol. 2001;116:168-176.
Brown RD, Gibson J, Petersen A, Wiley J, Joshua DE. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Leuk Lymphoma. 1997;27:83-91.